Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology · 2012
Mitroflow pericardial bioprosthesis: structured failure at 4.5 years.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Butany Jagdish, Feng Tianshu, Suri Rahul, Law Kelsey, Christakis George
Аннотация
BACKGROUND: Prosthetic heart valves are commonly used in the management of significant valvular disease. Although bioprostheses are increasingly popular, structural deterioration with cusp tears and calcification persists.
METHODS: We present a case of a Mitroflow pericardial bioprosthesis (Sorin Group Inc., Mitroflow Division, Vancouver, Canada) explanted after 4.5 years from a 78-year-old woman for bioprosthesis stenosis.
RESULTS: The morphological reasons for bioprosthesis failure include structural tissue deterioration with thickening of the pericardial cusps, cusp calcification, and parastent post tears resulting in significant valvular dysfunction.
CONCLUSION: To the best of our knowledge, this is the first detailed morphological description of the failure modes of a surgically explanted Mitroflow (A12) pericardial bioprosthesis.
METHODS: We present a case of a Mitroflow pericardial bioprosthesis (Sorin Group Inc., Mitroflow Division, Vancouver, Canada) explanted after 4.5 years from a 78-year-old woman for bioprosthesis stenosis.
RESULTS: The morphological reasons for bioprosthesis failure include structural tissue deterioration with thickening of the pericardial cusps, cusp calcification, and parastent post tears resulting in significant valvular dysfunction.
CONCLUSION: To the best of our knowledge, this is the first detailed morphological description of the failure modes of a surgically explanted Mitroflow (A12) pericardial bioprosthesis.